Exploring the dynamics, legalities and hurdles in a period of transition for Parallel Trade

SMi Group 4 - 5 February 2020, London, UK.
SMi presents Europe's leading 14th annual Parallel Trade conference, taking place in London. As the only B2B parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade.

The size of the EU market in pharmaceutical distribution is around €5bn, and the UK accounts for 22.7% of this figure. The sector has an annual import value of around £1bn, while the annual export figure approximates £600m.

The 2020 event will hold a particular place of significance on shortages of medicines, current and ongoing challenges posed by Parallel Trading, potential implications of Brexit and IP exhaustion rights.

Furthermore, the FMD (Falsified Medicines Directive) will be coming into effect in February 2020. This conference will give companies affected the perfect opportunity to discuss and consider the impact that the FMD implementation will have on their practices and on the market.

The benefits of attending

This conference is a must-attend show for anyone involved in the parallel trade industry within pharmaceuticals and life sciences. Attending the show gives you the chance to interact with and discuss common issues with leaders involved in all the areas of the parallel trade industry. Furthermore, this provides core information to further strengthen your industry knowledge and approaches.
  • Assessing the economic impact and dynamics of Parallel Trade
  • Reviewing how to overcome the challenges and hurdles in Parallel Trade
  • Understanding the underlying principles of the EU internal market and competition policies
  • Discussing the impact of Parallel trade on patient safety
  • What's the impact and consequences of a no deal Brexit on testing and clinical trials?
  • Impact on shortages, availability, accessibility and innovation
  • Assessing current EU legislative instruments and changes in IP framework
  • An update on current illegal trade cases and the Falsified Medicines Directive

Plus two pre-conference interactive workshops

Workshop A

Parallel Trade and Brexit... Where are we now?
Tushar Patel, Principal Consultant, Key Pharmaceuticals Ltd

Workshop B

Understanding IP, regulatory and competition law issues in pharmaceutical parallel trade
John Schmidt, Partner, Antitrust, Arnold & Porter Kaye Scholer

For more information and to register, please visit:
http://www.parallel-trade.com/wpnwl

Early-Bird Rates

  • Register by 31st October to save £400
  • Register by 29th November to save £200
  • Register by 13th December to save £100

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

A step closer to cancer precision medicine

Researchers from the Faculty of Medicine and the Institute for Molecular Medicine (FIMM) at the University of Helsinki have developed a computational model, Combined Esse...

Artificial Intelligence algorithm can learn the la…

Artificial Intelligence can be used to predict molecular wave functions and the electronic properties of molecules. This innovative AI method developed by a team of resea...

Amgen completes acquisition of Otezla® (apremilast…

Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for mo...

Bristol-Myers Squibb completes acquisition of Celg…

Bristol-Myers Squibb Company (NYSE:BMY) has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all governmen...

Amgen and the Duke Clinical Research Institute ann…

Amgen (NASDAQ:AMGN) in collaboration with the Duke Clinical Research Institute (DCRI) announced plans to initiate the Cardiovascular Multi-dimensional Observational Inves...

Statins not associated with memory or cognition de…

Given consumer concern that statins may be associated with memory or cognitive decline, a new study published today in the Journal of the American College of Cardiology m...

Novartis announces new strategy to provide innovat…

Novartis announced a new strategy to broaden patient reach and availability of its portfolio of medicines in sub-Saharan Africa (SSA), which is home to the largest unders...

New advances in the treatment of advanced lung can…

The University of Barcelona (UB) and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic an...

FDA grants priority review to Roche’s risdiplam fo…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for ...

A protein tag to study the immune system

Researchers from VIB-UGent Center for Medical Biotechnology, University of Iowa (USA) and other collaborators, developed a novel approach to better understand a basic def...

Bayer and Dewpoint Therapeutics partner to researc…

Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, today announced an option, research and license agreement worth up to ...

Pharmacist-led interventions may help prevent card…

With their expertise in the safe and effective use of medications, pharmacists can help in the management of chronic diseases. A review and analysis published in the Brit...